QTTB on XNAS, Health Care, Q32 Bio Inc., job postings
Measures activity, not value. Not investment advice.
Short interest now 19% of shares, 20 times its level a year earlier, while shares gained 332% in 12 months.
GoodNew institutional positions 48, 6.0 times a year earlier
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
expected around 9 Mar 2027 (an estimate: a year ago it reported on 10 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $8.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $92.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$8.9M
30 Jun 2026
–
-$8.9M
31 Mar 2026
–
-$7.6M
31 Dec 2025
–
$57.7M
30 Sep 2025
–
-$7.4M
30 Jun 2025
–
-$9.5M
31 Mar 2025
–
-$11.0M
31 Dec 2024
$0
–
30 Sep 2024
$0
-$17.6M
30 Jun 2024
$0
-$17.0M
31 Mar 2024
$0
$1.0M
31 Dec 2023
–
-$16.1M
30 Sep 2023
$0
-$33.0M
30 Jun 2023
$354K
-$35.0M
31 Mar 2023
$802K
-$28.8M
31 Dec 2022
$802K
-$34.3M
30 Sep 2022
$802K
-$33.7M
30 Jun 2022
$802K
-$29.1M
31 Mar 2022
$802K
$92.1M
31 Dec 2021
$802K
-$33.6M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$32.3M
-$42.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$289.6M
$49.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
$11.2M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
-$37.8M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$9.61
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
7.7
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.87
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$320K
bought $0, sold $320K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+46%
105 13F filers vs 72
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
31.5M shares held by 13F filers (30 Sep 2026) of 29.9M outstanding (31 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
19%
5.6M shares sold short (30 Oct 2026) of 29.9M outstanding (31 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
12.1
5.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-1.1%
5.7M shares sold short in the report before, 5.6M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
65%
65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
6
6 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
4.0×
6 articles in the last 7 days; its usual week has 1.5.
Unusual now sharp changes in the last 90 days, compared with its own past
New institutional positions 48, 6.0× a year earlier
Short interest 5.6M, 20× a year earlier
Price $8.34 on 20 Nov 2026, +332% over 12 months (12-month range $1.93 to $21.38)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $14.5M in the last 12 months (the 12 months before: -$32K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.Revenue per quarter. Revenue $0 in the latest quarter.Capital spending per quarter. Capital spending $0 in the latest quarter.Institutional holders (13F filers). 105 13F filers reported holding it in the latest 13F quarter, +106% on a year earlier.Lobbying spend. Lobbying spend: $0 published in the last 12 months.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $802K, -18% on a year earlier; public on 24 Mar 2022
Quarter ended 31 Mar 2022: $802K, -97% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $802K, -63% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $802K, -52% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $802K, 0% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $802K, 0% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $354K, -56% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $0; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 12 Mar 2025
Capital spending per quarter
Quarter ended 31 Dec 2021: $338K, -65% on a year earlier; public on 24 Mar 2022
Quarter ended 31 Mar 2022: $1.1M, +41% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $121K, -84% on a year earlier; public on 16 Aug 2022
Quarter ended 31 Dec 2022: $9K, -97% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $228K, -80% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $0; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $0, -100% on a year earlier; public on 14 Mar 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 10 May 2024
Quarter ended 30 Sep 2025: $0; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 11 Mar 2026
Institutional holders (13F filers)
31 Mar 2024 report: 37; public on 15 May 2024
30 Jun 2024 report: 52; public on 14 Aug 2024
30 Sep 2024 report: 70; public on 14 Nov 2024
31 Dec 2024 report: 88; public on 14 Feb 2025
31 Mar 2025 report: 70; public on 15 May 2025
30 Jun 2025 report: 55; public on 14 Aug 2025
30 Sep 2025 report: 51; public on 14 Nov 2025
31 Dec 2025 report: 53; public on 17 Feb 2026
31 Mar 2026 report: 52; public on 15 May 2026
30 Jun 2026 report: 72; public on 14 Aug 2026
30 Sep 2026 report: 105; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $20K published
Quarter from 1 Apr 2022: $20K published
Quarter from 1 Jul 2022: $20K published
What is unusual now
Made public in the last 90 days: it saw 48 13F filers open a new position in the quarter ended 30 Sep 2026, 6.0× the same quarter last year; it also had 5.6M shares sold short in the 30 Oct 2026 report, 20× the same report last year. 7 sharp changes in all. Two or more unrelated kinds of activity agreed on 17 Nov 2026.
Many funds opening a new position: saw 48 13F filers open a new position in the quarter ended 30 Sep 2026, 6.0× the same quarter last year Public on 16 Nov 2026.
Short interest spike: had 5.6M shares sold short in the 30 Oct 2026 report, 20× the same report last year Public on 11 Nov 2026.
In 12 months: 5 major agreements, 1 agreement ended, 1 completed deal, 1 director or officer change. Results releases and routine reports are left out.
Reported lobbying spend: $20K in Q2 2022, $20K in Q1 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
30 Jun 2022
Ended
Burrell International Group LLCfor Homology Medicines
Drug pricing, gene therapy, and rare disease funding generally; Advancing Access to Precision Medicine; Newborn Screening Saves Lives Reauthorization Act; Genome Editing Threat Assessment Act; Medical Nutrition Equity Act; STAT Act and Rare Disease Legislation proposalsMED
Two or more unrelated kinds of records unusual within 30 days
17 Nov 2026confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Q32 Bio(QTTB): had 5.6M shares sold short in the 30 Oct 2026 report, 20× the same report last year, while it saw 48 13F filers open a new position in the quarter ended 30 Sep 2026, 6.0× the same quarter last year. Two unrelated kinds of activity within 21 days.
Short interest and volume: Short interest spike, became public on 27 Oct 2026
Short interest and volume: Short interest spike, became public on 11 Nov 2026
Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
The 30 Oct 2026 report against the 24 reports before it.
this reportearliernormal: 531KSee the evidence (3 changes)
Short interest and volume: Short interest spike became public on 27 Oct 2026
Q32 Bio had 5.7M shares sold short in the 15 Oct 2026 report, 12× the same report last year.
This period
5.7M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
447K
Typical spread (median absolute deviation)
178K
How far from its usual level
+19.7
Same report last year
465K
History used
931 days
the 15 Oct 2026 report24 earlier reportsnormal: 447K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Nov 2026
Q32 Bio had 5.6M shares sold short in the 30 Oct 2026 report, 20× the same report last year.
This period
5.6M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
531K
Typical spread (median absolute deviation)
251K
How far from its usual level
+13.6
Same report last year
273K
History used
946 days
the 30 Oct 2026 report24 earlier reportsnormal: 531K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 16 Nov 2026
Q32 Bio saw 48 13F filers open a new position in the quarter ended 30 Sep 2026, 6.0× the same quarter last year.
This period
48 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
2
How far from its usual level
+13.0
Same quarter last year
8
History used
913 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 9
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
17 Nov 2026several at once
had 5.6M shares sold short in the 30 Oct 2026 report, 20× the same report last year, while it saw 48 13F filers open a new position in the quarter ended 30 Sep 2026, 6.0× the same quarter last year. Two unrelated kinds of activity within 21 days.
See the evidence (3 changes)
Short interest and volume: Short interest spike became public on 27 Oct 2026
Q32 Bio had 5.7M shares sold short in the 15 Oct 2026 report, 12× the same report last year.
This period
5.7M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
447K
Typical spread (median absolute deviation)
178K
How far from its usual level
+19.7
Same report last year
465K
History used
931 days
the 15 Oct 2026 report24 earlier reportsnormal: 447K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Nov 2026
Q32 Bio had 5.6M shares sold short in the 30 Oct 2026 report, 20× the same report last year.
This period
5.6M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
531K
Typical spread (median absolute deviation)
251K
How far from its usual level
+13.6
Same report last year
273K
History used
946 days
the 30 Oct 2026 report24 earlier reportsnormal: 531K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 16 Nov 2026
Q32 Bio saw 48 13F filers open a new position in the quarter ended 30 Sep 2026, 6.0× the same quarter last year.
This period
48 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
2
How far from its usual level
+13.0
Same quarter last year
8
History used
913 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 9
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 Nov 2026Institutional holdings change
saw 48 13F filers open a new position in the quarter ended 30 Sep 2026, 6.0× the same quarter last year.
Same quarter last year: 8; its normal quarter is 9.
See the evidence
This period
48 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
2
How far from its usual level
+13.0
Same quarter last year
8
History used
913 days
the quarter ended 30 Sep 20268 earlier quartersnormal: 9
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 5.6M shares sold short in the 30 Oct 2026 report, 20× the same report last year.
Same report last year: 273K; its normal report is 531K.
See the evidence
This period
5.6M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
531K
Typical spread (median absolute deviation)
251K
How far from its usual level
+13.6
Same report last year
273K
History used
946 days
the 30 Oct 2026 report24 earlier reportsnormal: 531K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.7M shares sold short in the 15 Oct 2026 report, 12× the same report last year.
Same report last year: 465K; its normal report is 447K.
See the evidence
This period
5.7M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
447K
Typical spread (median absolute deviation)
178K
How far from its usual level
+19.7
Same report last year
465K
History used
931 days
the 15 Oct 2026 report24 earlier reportsnormal: 447K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.7M shares sold short in the 30 Sep 2026 report, 17× the same report last year.
Same report last year: 278K; its normal report is 420K.
See the evidence
This period
4.7M (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
420K
Typical spread (median absolute deviation)
145K
How far from its usual level
+19.8
Same report last year
278K
History used
916 days
the 30 Sep 2026 report24 earlier reportsnormal: 420K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.8M shares sold short in the 15 Sep 2026 report, 13× the same report last year.
Same report last year: 288K; its normal report is 397K.
See the evidence
This period
3.8M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
397K
Typical spread (median absolute deviation)
119K
How far from its usual level
+19.2
Same report last year
288K
History used
901 days
the 15 Sep 2026 report24 earlier reportsnormal: 397K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.6M shares sold short in the 31 Aug 2026 report, 12× the same report last year.
Same report last year: 307K; its normal report is 374K.
See the evidence
This period
3.6M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
374K
Typical spread (median absolute deviation)
94K
How far from its usual level
+22.8
Same report last year
307K
History used
886 days
the 31 Aug 2026 report24 earlier reportsnormal: 374K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.1M shares sold short in the 14 Aug 2026 report, 8.8× the same report last year.
Same report last year: 356K; its normal report is 364K.
See the evidence
This period
3.1M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
364K
Typical spread (median absolute deviation)
84K
How far from its usual level
+22.3
Same report last year
356K
History used
869 days
the 14 Aug 2026 report24 earlier reportsnormal: 364K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.0M shares sold short in the 31 Jul 2026 report, 7.3× the same report last year.
Same report last year: 412K; its normal report is 364K.
See the evidence
This period
3.0M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
364K
Typical spread (median absolute deviation)
79K
How far from its usual level
+22.6
Same report last year
412K
History used
855 days
the 31 Jul 2026 report24 earlier reportsnormal: 364K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 862K shares sold short in the 29 May 2026 report, 1.9× the same report last year.
Same report last year: 460K; its normal report is 359K.
See the evidence
This period
862K (the 29 May 2026 report)
Normal report (median of 24 earlier)
359K
Typical spread (median absolute deviation)
70K
How far from its usual level
+4.8
Same report last year
460K
History used
792 days
the 29 May 2026 report24 earlier reportsnormal: 359K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $29.3M for the quarter ended 31 Mar 2021, 50× the same quarter last year.
Same quarter last year: $588K; its normal quarter is $565K.
See the evidence
This period
$29.3M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$565K
Typical spread (median absolute deviation)
$74K
How far from its usual level
+28.7
Same quarter last year
$588K
History used
1,096 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $565K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 61 entries; narrow the window or the kind of data to see older ones.
Not listed: 169 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001661998
Ticker
QTTB
Domain
q32bio.com
Employer name
Q32 Bio Inc (1 unverified)
Hq location
MA|WALTHAM|02451 (1 unverified)
Lobbying client
homology medicines
Name
Homology Medicines, Inc., Q32 Bio Inc.
DOL H-1B labor condition applications and PERM certifications26 data points1 Feb 2021 to 2 Jun 2025
Federal lobbying disclosures (LDA)2 records, 24 data points26 Aug 2020 to 30 Jun 2022
SEC Form 13F institutional holdings99 data points31 Mar 2024 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)110 records6 Jan 2016 to 4 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)574 data points31 Dec 2016 to 31 Oct 2026
SEC Form 4 insider transactions95 records, 192 data points4 Apr 2018 to 14 Oct 2026
FINRA short interest (twice monthly)189 data points28 Mar 2024 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)1336 data points26 Mar 2024 to 20 Nov 2026